Safety Assessment of an Anti-Obesity Drug (Sibutramine)A Retrospective Cohort Study

被引：0
作者：
Jerzy E. Tyczynski
Denise M. Oleske
David Klingman
Cheryl P. Ferrufino
Won Chan Lee
机构：
[1] Product Safety and Pharmacovigilance,Astellas Pharma Global Development, Inc.
[2] Global Surveillance and Pharmacoepidemiology,Abbott Laboratories
[3] Dept R4ED,Health Economics and Outcomes Research
[4] IMS Health Inc.,undefined
来源：
Drug Safety | 2012年 / 35卷 / 8期
关键词：
Acute Myocardial Infarction; Orlistat; Rimonabant; Sibutramine; Label Status;
D O I：
10.1007/BF03261960
中图分类号：
学科分类号：
摘要：
Background: Obesity is a serious and rapidly growing health problem worldwide. Few therapies are available beyond diet, exercise and bariatric surgery. A previously approved medication, sibutramine, has been withdrawn from the market due to concerns over the potential of increased risk of cardiovascular (CV) events, based on a phase IV clinical trial that included only individuals at high risk for CV events.
引用
收藏
页码：629 / 644
页数：15
相关论文
共 62 条
  • [51] Harrison-Woolrych M.(undefined)undefined undefined undefined undefined-undefined
  • [52] Ashton J.(undefined)undefined undefined undefined undefined-undefined
  • [53] Herbison P.(undefined)undefined undefined undefined undefined-undefined
  • [54] Perrio M.J.(undefined)undefined undefined undefined undefined-undefined
  • [55] Wilton L.V.(undefined)undefined undefined undefined undefined-undefined
  • [56] Shakir S.A.(undefined)undefined undefined undefined undefined-undefined
  • [57] Gaciong Z.(undefined)undefined undefined undefined undefined-undefined
  • [58] Placha G.(undefined)undefined undefined undefined undefined-undefined
  • [59] Berghofer A.(undefined)undefined undefined undefined undefined-undefined
  • [60] Pischon T.(undefined)undefined undefined undefined undefined-undefined
1234567